Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

{
  "signal_id": "df0081e9-96ca-0901-877a-3577ff57d226",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-08-27T12:30:00+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-npj-precision-oncology-study-showing-ai-guided-therapy-selection-is-predictive-of-longer-survival-in-patients-with-pancreatic-cancer-302861396.html",
    "title": "Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer",
    "excerpt": "Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas , Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI ), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature. In the testing cohort, standard molecular risk patients predicted to benefit from FOLFIRINOX achieved substantially longer median overall survival when treated with FOLFIRINOX rather than gemcitabine plus nab-paclitaxel (gem/nab-p) (16.0 vs 9.9 months). Approximately half of the patients in the study received a different first-line therapy than the model would have recommended, highlighting the potential opportunity for more biologically informed treatment selection to improve survival and reduce toxicity. The Caris AI Insights signature for pancreatic cancer is included in the Caris Molecular Tumor Board Report. This report, built using whole exome sequencing (WES) and whole transcriptome sequencing (WTS) data, is...",
    "product": "Caris AI Insights for pancreatic cancer",
    "summary": "Caris Life Sciences announced the publication of a study validating its AI-driven approach, Caris AI Insights, for optimizing first-line treatment selection in pancreatic cancer.",
    "location": "Irving, Texas, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS863020/Caris-Life-Sciences-Logo.jpg?id=OA2914973&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Caris AI Insights",
      "full_text": "Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature",
      "fuzzy_match": false
    },
    "product_tags": [
      "future_tech",
      "medical",
      "data"
    ],
    "published_at": "2026-08-27T12:30:00Z",
    "location_data": [
      {
        "city": "Irving",
        "state": "Texas",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-27",
    "article_sentence": "Caris Life Sciences ® (NASDAQ: CAI ), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies."
  }
}

curl https://signals.autobound.ai/v1/signals/df0081e9-96ca-0901-877a-3577ff57d226 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'